# Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct04606576` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04606576](<https://clinicaltrials.gov/study/NCT04606576>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04606576

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 710 participants.

## Technical summary

Registry record NCT04606576. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-15 (actual); primary completion 2023-01-13 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 710 participants (enrolled count; ClinicalTrials.gov record NCT04606576, source copy `cardio:ctgov-nct04606576-2023-02-09`, retrieved 2026-10-26)
- Started: 2020-12-15 (actual) (ClinicalTrials.gov record NCT04606576, source copy `cardio:ctgov-nct04606576-2023-02-09`, retrieved 2026-10-26)
- Primary completion: 2023-01-13 (actual) (ClinicalTrials.gov record NCT04606576, source copy `cardio:ctgov-nct04606576-2023-02-09`, retrieved 2026-10-26)
- Completion: 2023-01-13 (actual) (ClinicalTrials.gov record NCT04606576, source copy `cardio:ctgov-nct04606576-2023-02-09`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04606576, source copy `cardio:ctgov-nct04606576-2023-02-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04606576-2023-02-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes Mellitus
- Intervention (Other): Placebo
- Intervention (Drug): ORMD-0801 QD
- Intervention (Drug): ORMD-0801 BD
- Lead sponsor: Oramed, Ltd.
- Lead sponsor class: INDUSTRY
- Collaborator: Integrium
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Oramed, Ltd. (`cardio:org-oramed-ltd`)
- Registry lists this organization as a collaborator: Integrium (`cardio:org-integrium`)

## Provenance

Content hash: 15df71106314088aaf17112ce6872cea1515cfcee9663f9d15815744978fd967
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
